News

Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting

MENLO PARK, Calif.— March 2, 2022 — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that data from clinical studies of the OMNI® Surgical System will be presented at the 2022 American Glaucoma Society (AGS) Annual Meeting. The conference […]

Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting Read More »

Deborah L. Rice-Johnson – Mindera Health

Ms. Rice-Johnson has more than 30 years of experience in the health insurance industry and is CEO of Diversified Businesses for Highmark Inc. and chief growth officer. Her leadership has not only redefined the payer-provider relationship and yielded unparalleled financial performance, but she has also delivered innovative clinical solutions that aim to improve health outcomes. Her

Deborah L. Rice-Johnson – Mindera Health Read More »

Mindera Health™ Appoints Deborah L. Rice-Johnson to its Board of Directors

SAN DIEGO, CA – March 1, 2022 – Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,   has appointed Deborah L. Rice-Johnson to its Board of Directors, effective February 28, 2022.  Ms. Rice-Johnson has more than 30 years of experience in the health insurance industry.

Mindera Health™ Appoints Deborah L. Rice-Johnson to its Board of Directors Read More »

Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma

MENLO PARK, Calif.— February 17, 2022 — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive

Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma Read More »

Empirical Spine Advances LimiFlex™ as a New Motion-Preserving, Minimally Invasive Standard in Spine Surgery — Empirical Spine

2021 Brought Breakthrough Device Designation and PMA Process Initiation San Carlos, Calif. (February 1, 2022) – Empirical Spine, Inc., a medical device company creating a new class of spinal implant that works in parallel with the natural structures of the spine to restore functionality and optimize quality of life, achieved several clinical, reimbursement and regulatory

Empirical Spine Advances LimiFlex™ as a New Motion-Preserving, Minimally Invasive Standard in Spine Surgery — Empirical Spine Read More »

Lisa Garrett Joins Channel Medsystems Board of Directors

Berkeley, California January. 25, 2022  Channel Medsystems, Inc. a medical device company dedicated to bringing innovation to the delivery of women’s healthcare, today announced that Lisa Garrett has joined the company’s Board of Directors. “Lisa brings a wealth of financial leadership experience at large and emerging companies in the healthcare industry,” said Ric Cote, Chief Executive

Lisa Garrett Joins Channel Medsystems Board of Directors Read More »

Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients

Partnership to focus on improving patient outcomes while reducing healthcare system costs of expensive biologic therapeutics SAN DIEGO, CA and LAKELAND, FL – January 4, 2022 – Mindera Health™ and WellDyne have entered into a definitive agreement to improve the management of psoriasis patients with moderate to severe disease using a proprietary dermal biomarker patch

Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients Read More »

Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

MENLO PARK, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the TearCare® System for the treatment of meibomian gland dysfunction (MGD),

Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease Read More »